| Trial ID: | L0270 |
| Source ID: | NCT04152473
|
| Associated Drug: |
Proglumide
|
| Title: |
Safety and Tolerability of Oral Proglumide for NASH
|
| Acronym: |
STOPNASH
|
| Status: |
Active, not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Proglumide
|
| Outcome Measures: |
safety and toxicity|Recommended Phase 2 dose|Liver transaminases
|
| Sponsor/Collaborators: |
Georgetown University
|
| Gender: |
All
|
| Age: |
18 Years to 85 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
18
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other
|
| Start Date: |
December 13, 2019
|
| Completion Date: |
September 9, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 15, 2022
|
| Locations: |
Georgetown University, Washington, District of Columbia, United States|Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04152473
|
